Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression.
Mor
E
E
Department of Surgery, Mount Sinai Medical Center New York, NY 10029.
Sheiner
P A
PA
Schwartz
M E
ME
Emre
S
S
Guy
S
S
Miller
C M
CM
D016572:Cyclosporine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D016031:Liver Transplantation / Q000276:immunology; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use* / Q000633:toxicity
D016572:Cyclosporine; D016559:Tacrolimus